Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

An International Space Station (ISS) resupply mission in 2026 will send up the Sierra Space trash compactor for testing, company officials stated in a press release on Wednesday (Oct. 16).

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

An illustration of Vast Space's Haven-2 station. Image: Vast Space NASA’s International Space Station (ISS) has been dominating low Earth orbit for more than 25 years, housing groups of ...

Troubleshooting the leaking ISS is ongoing, with NASA and Russia now identifying 50 "areas of concern" and four cracks, according to a media report. NASA and its Russian counterpart have ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Three NASA astronauts who recently returned from the International Space Station (ISS) have said that they are in good health but have declined to discuss the medical issue that required them to ...

Ivonescimab achieves hazard ratio of 0.51, beating pembrolizumab in progression-free survival. Summit Therapeutics targets potential $17.9 billion in peak revenue in NSCLC market by 2034. JMP ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

The leak has been ongoing since 2019 in the Russian segment of the International Space Station (ISS) and was the focus of a new report from NASA's Office of the Inspector General (OIG) published ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...